نتایج جستجو برای: factor viii and factor ix inhibitor
تعداد نتایج: 16983528 فیلتر نتایج به سال:
Enhanced half-life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients, for example, those with a past history of an inhibitor, have been excluded from clinical trials and there are limited data published on children....
The treatment of acquired haemophilia is characteristically exceedingly expensive and thus a cost-benefit analysis of the several available treatment strategies is urgently needed. To address this issue, decision-analysis techniques were used to construct a cost-minimization model to compare the cost of treatment with porcine factor VIII (pFVIII), human FVIII (hFVIII) or an activated prothrombi...
Submit Manuscript | http://medcraveonline.com Abbreviations: APDE: Acquired Platelet Dysfunction with Eosinophilia; AEC: Absolute Eosinophil Count; ADP: Adenosine Diphosphate; RiCof: Platelet Ristocetin Cofactor; APTT: Activated Partial Thromboplastin Time; PT: Prothrombin Time; SFLC: Serum Free Light Chains; IgA: Immunoglobulin A; aVWD: Acquired Von Willebrand Disease; FVIII: Factor VIII; FIX:...
is a congenital, often familial, hemorrhagic disorder which was distinguished from classical hemophilia (AHG deficiency, factor VIII deficiency, hemophilia A) in 1952.13 Like the latter, it is usually inherited as a sex-linked recessive trait: only the male hemizygote for the abnormal gene is clinically affected, and the female heterozygote or carrier is asymptomatic. From a eugenic standpoint ...
UNLABELLED Here, we report about a boy (age: 18 years) who developed an acquired factor VIII inhibitor at the age of 9 years. He presented with bleeding in his right ankle, multiple haematomas and a high-titer factor VIII type II inhibitor (400 BU). THERAPY He received treatment with MMF (CellCept®), dexamethasone-immunoglobulin pulses, and rituximab together with high dose FVIII (Hannover pr...
INTRODUCTION Patients with severe hemophilia A often develop inhibitors (antibodies) against transfused factor VIII. MATERIAL/METHODS One hundred thirteen Polish patients with severe hemophilia A, who had been treated on demand with cryoprecipitate until 1992 and exclusively with factor VIII concentrates after 1995, were examined for intron 22 inversion by Southern blotting and the presence a...
Here, we report about a boy (age: 18 years) who developed an acquired factor VIII inhibitor at the age of 9 years. He presented with bleeding in his right ankle, multiple haematomas and a high-titer factor VIII type II inhibitor (400 BU). Therapy: He received treatment with MMF (CellCept®), dexamethasoneimmunoglobulin pulses, and rituximab together with high dose FVIII (Hannover protocol). His ...
Hemophilia is treated by IV replacement therapy with Factor VIII (FVIII) or Factor IX (FIX), either on demand to resolve bleeding, or as prophylaxis. Improved treatment may be provided by drugs designed for subcutaneous and less frequent administration with a reduced risk of inhibitor formation. Tissue factor pathway inhibitor (TFPI) down-regulates the initiation of coagulation by inhibition of...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید